Skip to main content

Table 1 Baseline characteristics of main CvLPRIT trial and immediate versus staged in-hospital complete revascularisation CMR substudy participants

From: Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study

Variable CvLPRIT cohort
(n = 296)
Immediate CR
(n = 63)
Staged CR
(n = 30)
p
Age (y) 64.9 ± 11.6 63.0 ± 11.6 65.0 ± 10.3 0.42
Male sex (%) 240/296 (81.1) 55 (87.3) 28 (93.3) 0.38
BMI (kg/m2) 27.3 (24.4–30.2) 27.7 ± 4.5 27.6 ± 4.1 0.95
Heart rate (beats per minute) 74.4 ± 17.6 71.9 ± 16.4 73.5 ± 18.0 0.68
Systolic BP (mmHg) 137.6 ± 27.1 132.6 ± 26.8 140.0 ± 27.7 0.23
Anterior infarct (%) 106 (35.6) 21 (33.3) 11 (36.7) 0.75
eGFR (ml/min/1.73) 95.74 ± 34.7 96.1 ± 30.2 101.5 ± 41.0 0.49
Hypertension (%) 105/287 (36.6) 24 (38.1) 10 (33.3) 0.66
Hypercholesterolemia (%) 75/287 (26.1) 16 (25.4) 12 (40.0) 0.15
Diabetes Mellitus (%) 39/287 (13.6) 11 (17.5) 4 (13.3) 0.61
Current smoker (%) 87/285 (30.5) 23 (36.5) 10 (33.3) 0.77
Previous MI (%) 12/287 (4.2) 4 (6.3) 0 (0.0) 0.16
Previous PCI (%) 9/287 (3.1) 4 (6.3) 0 (0.0) 0.16
Anti-anginal medication (B/N) 54/287 (18.8) 8/63 (12.7) 5/29 (17.2) 0.56
Killip Class II-III (%) 24/286 (8.4) 4 (6.3) 2 (6.7) 0.95
  1. Abbreviations: CR complete revascularization, BME black or minority ethnicity, BMI body mass index, eGFR estimated glomerular filtration rate, CK creatine kinase, MI myocardial infarction, PCI percutaneous coronary intervention
  2. Anti-anginal medication (B/N) = beta-blocker or nitrate at admission